What happened with ABEO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Abeona Therapeutics makes ZEVASKYN for wounds in adults and children with recessive dystrophic epidermolysis bullosa, an inherited skin disease. A treatment center sends a patient’s skin biopsy to Abeona’s Cleveland facility, where the company corrects a gene in the patient’s skin cells and grows them into sheets. After testing, it ships the sheets back for surgical application. The centers buy ZEVASKYN directly from Abeona; commercial insurers and government health programs provide coverage for treatment.
Commercial treatment has only recently begun, and ZEVASKYN is Abeona’s only approved product. Sales depend on eligible patients reaching qualified centers, successful patient-specific manufacturing and delivery, and payer reimbursement. FDA approval covers the specified wound treatment, and each batch must meet release requirements before use.
Licensing has contributed more reported revenue than product sales, chiefly through a development milestone paid under its Taysha sublicense for an investigational Rett syndrome gene therapy. These payments depend on contractual milestones rather than patient treatments. Abeona also has eye-disease gene therapies in preclinical development, not approved products.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Abeona’s outlook hinges on treatment centers adopting ZEVASKYN and securing reimbursement in an RDEB wound-care market that also includes Chiesi’s approved Filsuvez.
Krystal Biotech competes with Abeona for RDEB patients and treatment spending: it sells VYJUVEK, a gene therapy applied to DEB wounds, while Abeona supplies ZEVASKYN sheets made from a patient’s own gene-modified cells. Watch VYJUVEK product revenue for evidence of spending on this competing treatment.
Taysha Gene Therapies pays Abeona for licensed Rett syndrome gene-therapy rights, so its development progress can generate milestone revenue for Abeona, with royalties possible on future sales. Dosing the first patient in its REVEAL pivotal trial in December 2025 triggered a $3 million payment to Abeona, making TSHA-102 trial progress worth watching.
Ultragenyx Pharmaceutical has taken over development of Abeona’s licensed UX111 gene therapy for MPS IIIA; Abeona is eligible for commercial milestones and royalties on net sales after regulatory approval. UX111’s approval progress is therefore the first thing to watch for this potential income stream.
Krystal Biotech, Inc. earningsKRYS
Krystal Biotech, Inc.'s report will show how much patients and treatment centers are spending on VYJUVEK in the RDEB market it shares with Abeona Therapeutics Inc.
Watch the change in VYJUVEK product revenue. Rising revenue would show that this gene therapy for DEB wounds is drawing more treatment spending, intensifying competition for Abeona’s RDEB patients and treatment-center resources. Falling revenue would show weaker momentum for this alternative, but would not establish that patients are turning to ZEVASKYN.
Taysha Gene Therapies, Inc. earningsTSHA
Taysha Gene Therapies, Inc.'s report will show whether REVEAL trial progress brings Abeona Therapeutics Inc. milestone income under their Rett syndrome license agreement.
Watch for Taysha’s disclosed progress in the REVEAL pivotal trial and whether it triggers a payment to Abeona under the agreement. A new milestone payment would show that development of the licensed program has generated licensing income for Abeona. Without one, potential income remains dependent on future progress and contract terms, not a steady stream of product sales.
Abeona Therapeutics Inc. earningsThis company
Abeona Therapeutics Inc.'s report will show whether ZEVASKYN sales are beginning to support the business, rather than leaving it reliant on occasional licensing income and cash on hand.
Read ZEVASKYN product revenue alongside operating cash use, and distinguish any licensing income tied to a one-off milestone. Higher product revenue with lower operating cash use would show patient-specific treatments passing treatment-center inspection are building a firmer commercial base. Persistently low product revenue and heavy cash use would show sales have not caught up with research and operating costs; a one-off licensing payment would not prove the commercial business is established.
